BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Tumors
Neoplasm Metastasis

Interventions: Drug: Brivanib
Drug: Brivanab

First Posted Date: 2005-09-21

Last Posted Date: 2008-11-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 68

Registration Number: NCT00207103

Locations: 🇺🇸
Premiere Oncology, Santa Monica, California, United States
🇺🇸
University Of Wisconsin Comprehensive Center, Madison, Wisconsin, United States
🇬🇧
Local Institution, Manchester, Greater Manchester, United Kingdom

and more 1 locations

A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Tumors

First Posted Date: 2005-09-21

Last Posted Date: 2010-03-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT00207025

Locations: 🇧🇪
Local Institution, Brussels, Belgium

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Brivanib + Cetuximab

First Posted Date: 2005-09-21

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 62

Registration Number: NCT00207051

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 3 locations

Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)

Phase 2

Completed

Conditions: Staphylococcus Aureus Bacteremia

First Posted Date: 2005-09-20

Last Posted Date: 2013-03-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT00198302

Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs

Phase 2

Completed

Conditions: Staphylococcus Aureus

First Posted Date: 2005-09-20

Last Posted Date: 2013-03-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT00198289

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

Abatacept With Methotrexate- Phase IIB

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept (BMS-188667)
Drug: Placebo

First Posted Date: 2005-09-13

Last Posted Date: 2012-06-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 524

Registration Number: NCT00162266

Locations: 🇬🇧
Local Institution, Leeds, Yorkshire, United Kingdom

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Conditions: HIV Infection

First Posted Date: 2005-09-13

Last Posted Date: 2014-01-09

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00162227

Locations: 🇺🇸
Children'S Hospital, Boston, Massachusetts, United States
🇺🇸
State University Of New York At Stony Brook, Stony Brook, New York, United States
🇺🇸
Metro Health Medical Center, Cleveland, Ohio, United States

and more 21 locations

Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment

Phase 1

Completed

Conditions: HIV Infections
Hepatic Impairment

Interventions: Drug: efavirenz containing antiretroviral regimen

First Posted Date: 2005-09-13

Last Posted Date: 2010-09-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 21

Registration Number: NCT00162097

Locations: 🇮🇹
Local Institution, Milano, Italy
🇺🇸
Uthscsa, San Antonio, Texas, United States
🇺🇸
Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States

and more 1 locations

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2005-09-13

Last Posted Date: 2017-01-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT00162201

Locations: 🇬🇧
Local Institution, Leeds, Essex, United Kingdom

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada

Conditions: HIV Infection

First Posted Date: 2005-09-13

Last Posted Date: 2014-01-09

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00162188

Locations: 🇨🇦
Local Institution, Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy